Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma

Next Previous
Trial Profile

A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms DREAM
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 24 May 2023 Meta analysis from NCT01000506, NCT01691521, NCT01287039, NCT01285323, NCT01928771, and NCT01914757, presented at the 119th International Conference of the American Thoracic Society.
    • 06 Aug 2021 Results of a pooled analysis predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide from following clinical studies: Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1 & 2 and DREAM using biomarker-stratified trial-level attack rates published in the Thorax
    • 16 Mar 2020 Results of A post hoc analysis of data from DREAM, MENSA and MUSCA Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top